KREBSBIO Stock Overview
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Krebs Biochemicals & Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹70.70 |
| 52 Week High | ₹93.95 |
| 52 Week Low | ₹59.20 |
| Beta | 0.47 |
| 1 Month Change | 8.02% |
| 3 Month Change | -4.33% |
| 1 Year Change | -3.42% |
| 3 Year Change | -38.60% |
| 5 Year Change | -32.34% |
| Change since IPO | -30.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| KREBSBIO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.0% | -2.5% | -2.5% |
| 1Y | -3.4% | 55.2% | 44.5% |
Return vs Industry: KREBSBIO underperformed the Indian Pharmaceuticals industry which returned 55.2% over the past year.
Return vs Market: KREBSBIO underperformed the Indian Market which returned 44.5% over the past year.
Price Volatility
| KREBSBIO volatility | |
|---|---|
| KREBSBIO Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: KREBSBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: KREBSBIO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 210 | Jitendra Shah | krebsbiochem.com |
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications.
Krebs Biochemicals & Industries Limited Fundamentals Summary
| KREBSBIO fundamental statistics | |
|---|---|
| Market cap | ₹1.55b |
| Earnings (TTM) | -₹208.21m |
| Revenue (TTM) | ₹499.09m |
3.1x
P/S Ratio-7.3x
P/E RatioIs KREBSBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KREBSBIO income statement (TTM) | |
|---|---|
| Revenue | ₹499.09m |
| Cost of Revenue | ₹88.84m |
| Gross Profit | ₹410.25m |
| Other Expenses | ₹618.46m |
| Earnings | -₹208.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.66 |
| Gross Margin | 82.20% |
| Net Profit Margin | -41.72% |
| Debt/Equity Ratio | -173.3% |
How did KREBSBIO perform over the long term?
See historical performance and comparison